168 related articles for article (PubMed ID: 402652)
1. The sphiningolipidoses: an overview.
West HH
Postgrad Med; 1977 Mar; 61(3):90-3, 95. PubMed ID: 402652
[TBL] [Abstract][Full Text] [Related]
2. Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases.
Inui K; Wenger DA
J Clin Invest; 1983 Nov; 72(5):1622-8. PubMed ID: 6415115
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy of Sphingolipid Metabolic Disorders.
Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
[TBL] [Abstract][Full Text] [Related]
4. Basic findings and current developments in sphingolipidoses.
Pilz H; Heipertz R; Seidel D
Hum Genet; 1979 Mar; 47(2):113-34. PubMed ID: 108196
[TBL] [Abstract][Full Text] [Related]
5. Sphingolipidoses in Turkey.
Ozkara HA; Topçu M
Brain Dev; 2004 Sep; 26(6):363-6. PubMed ID: 15275696
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
[TBL] [Abstract][Full Text] [Related]
7. [Activator protein for the enzymic hydrolysis of sphingolipids and their relationships to sphingolipidosis. Special reference to the catabolism of GM2 ganglioside].
Hirabayashi Y; Li YT; Li SC
Seikagaku; 1983; 55(1):1-13. PubMed ID: 6405000
[No Abstract] [Full Text] [Related]
8. Sphingolipid metabolism in neural tissues.
Brady RO
Neurosci Res (N Y); 1969; 2(0):301-15. PubMed ID: 4950732
[No Abstract] [Full Text] [Related]
9. Application of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in cultured skin fibroblasts from sphingolipidosis patients.
Fujiwaki T; Yamaguchi S; Sukegawa K; Taketomi T
Brain Dev; 2002 Apr; 24(3):170-3. PubMed ID: 11934514
[TBL] [Abstract][Full Text] [Related]
10. [Differential diagnosis of congenital lipidoses by lipid analyses of body fluids, biopsy and autopsy tissue].
Pilz H; Heipertz R
Fortschr Neurol Psychiatr Grenzgeb; 1975 Nov; 43(11):602-17. PubMed ID: 53174
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease.
Pettazzoni M; Froissart R; Pagan C; Vanier MT; Ruet S; Latour P; Guffon N; Fouilhoux A; Germain DP; Levade T; Vianey-Saban C; Piraud M; Cheillan D
PLoS One; 2017; 12(7):e0181700. PubMed ID: 28749998
[TBL] [Abstract][Full Text] [Related]
12. Application of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in tissues from sphingolipidosis patients.
Fujiwaki T; Yamaguchi S; Sukegawa K; Taketomi T
J Chromatogr B Biomed Sci Appl; 1999 Aug; 731(1):45-52. PubMed ID: 10491988
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in sphingolipidosis research].
Tamai Y; Kojima H
Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1291-303. PubMed ID: 1972585
[No Abstract] [Full Text] [Related]
14. Membrane lipids and their degradation compounds control GM2 catabolism at intralysosomal luminal vesicles.
Anheuser S; Breiden B; Sandhoff K
J Lipid Res; 2019 Jun; 60(6):1099-1111. PubMed ID: 30988135
[TBL] [Abstract][Full Text] [Related]
15. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.
Bradová V; Smíd F; Ulrich-Bott B; Roggendorf W; Paton BC; Harzer K
Hum Genet; 1993 Sep; 92(2):143-52. PubMed ID: 8370580
[TBL] [Abstract][Full Text] [Related]
16. Inherited lipid storage diseases of the central nervous system.
Percy AK; Shapiro LJ; Kaback MM
Curr Probl Pediatr; 1979 Sep; 9(11):1-51. PubMed ID: 117977
[No Abstract] [Full Text] [Related]
17. [A sphingolipidosis with the accumulation of neutral glycosphingolipids, AO2(GM3) and A1(GM2)-ganglioside (author's transl)].
Kerènyi L; Kannan R; Gielen W; Debuch H
Z Klin Chem Klin Biochem; 1974 Nov; 12(11):487-93. PubMed ID: 4216195
[No Abstract] [Full Text] [Related]
18. Enzymatic abnormalities in diseases of sphingolipid metabolism.
Brady RO
Clin Chem; 1967 Jul; 13(7):565-77. PubMed ID: 5006481
[No Abstract] [Full Text] [Related]
19. From sheep to mice to cells: tools for the study of the sphingolipidoses.
Zigdon H; Meshcheriakova A; Futerman AH
Biochim Biophys Acta; 2014 Aug; 1841(8):1189-99. PubMed ID: 24607565
[TBL] [Abstract][Full Text] [Related]
20. Further developments in studies in sphingolipidoses: "missing enzymes".
Brady RO
Riv Patol Nerv Ment; 1970 Oct; 91(5):263-73. PubMed ID: 5525771
[No Abstract] [Full Text] [Related]
[Next] [New Search]
